Recent insights into the pathogenesis of type AA amyloidosis

TheScientificWorldJournal

Volumn 11, Issue , 2011, Pages 641-650

  Van Der Hilst, J C H ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b JESSA HOSPITAL   (Belgium)

Author keywords

Amyloidosis; Autoinflammatory diseases; Heat shock proteins; Isoprenoid metabolism; Serum amyloid A

Indexed keywords

AMYLOID; AMYLOID ENHANCING FACTOR; CATHEPSIN D; CHAPERONE; CYTOKINE; FARNESYL PHOSPHATE; GELATINASE A; GERANYLGERANYL PHOSPHATE; HEAT SHOCK PROTEIN 110; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; INTERSTITIAL COLLAGENASE; ISOPRENOID; PROTEIN DNAJ; PROTEIN GRPE; SERUM AMYLOID A; SMALL HEAT SHOCK PROTEIN; STROMELYSIN; UNCLASSIFIED DRUG;

AMYLOIDOSIS; CINCA SYNDROME; CLINICAL FEATURE; DNA POLYMORPHISM; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; INFLAMMATORY DISEASE; LIVER; PERIODIC FEVER SYNDROME; PROTEIN STRUCTURE; RISK FACTOR; SHORT SURVEY; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; TYPE AA AMYLOIDOSIS;

AMYLOIDOSIS; CATHEPSIN D; HEAT-SHOCK PROTEINS; HUMANS; MOLECULAR CHAPERONES; PROTEIN CONFORMATION; RISK FACTORS; SERUM AMYLOID A PROTEIN;

EID: 79955128743     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2011.64     Document Type: Short Survey

References (82)

1. Merlini, G. and Bellotti, V. (2003) Molecular mechanisms of amyloidosis. N. Engl. J. Med. 349, 583-596.
2. Westermark, P., Benson, M.D., Buxbaum, J.N., Cohen, A.S., Frangione, B., Ikeda, S., et al. (2002) Amyloid fibril protein nomenclature - 2002. Amyloid 9, 197-200. (Pubitemid 35205211)
3. Gertz, M.A. and Kyle, R.A. (1991) Secondary systemic amyloidosis: response and survival in 64 patients. Medicine (Baltimore) 70, 246-256.
4. Hamed, G., Heffess, C.S., Shmookler, B.M., and Wenig, B.M. (1995) Amyloid goiter. A clinicopathologic study of 14 cases and review of the literature. Am. J. Clin. Pathol. 104, 306-312.
5. Tuglular, S., Yalcinkaya, F., Paydas, S., Oner, A., Utas, C., Bozfakioglu, S., et al. (2002) A retrospective analysis for aetiology and clinical findings of 287 secondary amyloidosis cases in Turkey. Nephrol. Dial. Transplant. 17, 2003-2005.
6. Hazenberg, B.P., van Gameren, I.I., Bijzet, J., Jager, P.L., and van Rijswijk, M.H. (2004) Diagnostic and therapeutic approach of systemic amyloidosis. Neth. J. Med. 62, 121-128.
7. Janssen, S., van Rijswijk, M.H., Meijer, S., Ruinen, L., and Van der Hem, G.K. (1986) Systemic amyloidosis: a clinical survey of 144 cases. Neth. J. Med. 29, 376-385.
8. Tanaka, F., Migita, K., Honda, S., Fukuda, T., Mine, M., Nakamura, T., et al. (2003) Clinical outcome and survival of secondary (AA) amyloidosis. Clin. Exp. Rheumatol. 21, 343-346.
9. Joss, N., McLaughlin, K., Simpson, K., and Boulton-Jones, J.M. (2000) Presentation, survival and prognostic markers in AA amyloidosis. QJM 93, 535-542. (Pubitemid 30627402)
10. Gillmore, J.D., Lovat, L.B., Persey, M.R., Pepys, M.B., and Hawkins, P.N. (2001) Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 358, 24-29. (Pubitemid 32709735)
11. Uhlar, C.M. and Whitehead, A.S. (1999) Serum amyloid A, the major vertebrate acute-phase reactant. Eur. J. Biochem. 265, 501-523.
12. Hari-Dass, R., Shah, C., Meyer, D.J., and Raynes, J.G. (2005) Serum amyloid A protein binds to outer membrane protein A of Gram-negative bacteria. J. Biol. Chem. 280, 18562-18567.
13. Xu, L., Badolato, R., Murphy, W.J., Longo, D.L., Anver, M., Hale, S., et al. (1995) A novel biologic function of serum amyloid A. Induction of T lymphocyte migration and adhesion. J. Immunol. 155, 1184-1190.
14. Banka, C.L., Yuan, T., de Beer, M.C., Kindy, M., Curtiss, L.K., and de Beer, F.C. (1995) Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux. J. Lipid Res. 36, 1058-1065.
15. Liang, J.S. and Sipe, J.D. (1995) Recombinant human serum amyloid A (apoSAAp) binds cholesterol and modulates cholesterol flux. J. Lipid Res. 36, 37-46.
16. Liepnieks, J.J., Kluve-Beckerman, B., and Benson, M.D. (1995) Characterization of amyloid A protein in human secondary amyloidosis: the predominant deposition of serum amyloid A1. Biochim. Biophys. Acta 1270, 81-86.
17. Husebekk, A., Skogen, B., Husby, G., and Marhaug, G. (1985) Transformation of amyloid precursor SAA to protein AA and incorporation in amyloid fibrils in vivo. Scand. J. Immunol. 21, 283-287.
18. Rocken, C., Menard, R., Buhling, F., Vockler, S., Raynes, J., Stix, B., et al. (2005) Proteolysis of serum amyloid A and AA amyloid proteins by cysteine proteases: cathepsin B generates AA amyloid proteins and cathepsin L may prevent their formation. Ann. Rheum. Dis. 64, 808-815.
19. Stevens, F.J. (2004) Hypothetical structure of human serum amyloid A protein. Amyloid 11, 71-80.
20. Rubin, N., Perugia, E., Goldschmidt, M., Fridkin, M., and Addadi, L. (2008) Chirality of amyloid suprastructures. J. Am. Chem. Soc. 130, 4602-4603.
21. Kluve-Beckerman, B., Manaloor, J., and Liepnieks, J.J. (2001) Binding, trafficking and accumulation of serum amyloid A in peritoneal macrophages. Scand. J. Immunol. 53, 393-400.
22. Kluve-Beckerman, B., Manaloor, J.J., and Liepnieks, J.J. (2002) A pulse-chase study tracking the conversion of macrophage-endocytosed serum amyloid A into extracellular amyloid. Arthritis Rheum. 46, 1905-1913. (Pubitemid 34774523)
23. Li, J.P., Galvis, M.L., Gong, F., Zhang, X., Zcharia, E., Metzger, S., et al. (2005) In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis. Proc. Natl. Acad. Sci. U. S. A. 102, 6473-6477.
24. Tennent, G.A., Lovat, L.B., and Pepys, M.B. (1995) Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc. Natl. Acad. Sci. U. S. A. 92, 4299-4303.
25. Gellermann, G.P., Appel, T.R., Tannert, A., Radestock, A., Hortschansky, P., Schroeckh, V., et al. (2005) Raft lipids as common components of human extracellular amyloid fibrils. Proc. Natl. Acad. Sci. U. S. A. 102, 6297-6302.
26. Goldschmidt, L., Teng, P.K., Riek, R., and Eisenberg, D. (2010) Identifying the amylome, proteins capable of forming amyloid-like fibrils. Proc. Natl. Acad. Sci. U. S. A. 107, 3487-3492.
27. Gershoni-Baruch, R., Brik, R., Zacks, N., Shinawi, M., Lidar, M., and Livneh, A. (2003) The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum. 48, 1149-1155. (Pubitemid 36418258)
28. Cazeneuve, C., Ajrapetyan, H., Papin, S., Roudot-Thoraval, F., Genevieve, D., Mndjoyan, E., et al. (2000) Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. Am. J. Hum. Genet. 67, 1136-1143.
29. Altiok, O., Seguret, F., and Touitou, I. (2003) MEFV sequence variants and amyloidosis: still an enigmatic question. Hum. Mutat. 21, 96-97.
30. Yilmaz, E., Balci, B., Kutlay, S., Ozen, S., Erturk, S., Oner, A., et al. (2003) Analysis of the modifying effects of SAA1, SAA2 and TNF-alpha gene polymorphisms on development of amyloidosis in FMF patients. Turk. J. Pediatr. 45, 198-202.
31. Muller, D., Roessner, A., and Rocken, C. (2000) Distribution pattern of matrix metalloproteinases 1, 2, 3, and 9, tissue inhibitors of matrix metalloproteinases 1 and 2, and alpha 2-macroglobulin in cases of generalized AA- and AL amyloidosis. Virchows Arch. 437, 521-527.
32. Lee, H.Y., Kim, M.K., Park, K.S., Bae, Y.H., Yun, J., Park, J.I., et al. (2005) Serum amyloid A stimulates matrix-metalloproteinase-9 upregulation via formyl peptide receptor like-1-mediated signaling in human monocytic cells. Biochem. Biophys. Res. Commun. 330, 989-998.
33. Migita, K., Kawabe, Y., Tominaga, M., Origuchi, T., Aoyagi, T., and Eguchi, K. (1998) Serum amyloid A protein induces production of matrix metalloproteinases by human synovial fibroblasts. Lab. Invest. 78, 535-539.
34. Stix, B., Kahne, T., Sletten, K., Raynes, J., Roessner, A., and Rocken, C. (2001) Proteolysis of AA amyloid fibril proteins by matrix metalloproteinases-1, -2, and -3. Am. J. Pathol. 159, 561-570. (Pubitemid 32751086)
35. van der Hilst, J.C., Yamada, T., Op den Camp, H.J., van der Meer, J.W., Drenth, J.P., and Simon, A. (2008) Increased susceptibility of serum amyloid A 1.1 to degradation by MMP-1: potential explanation for higher risk of type AA amyloidosis. Rheumatology (Oxford) 47, 1651-1654.
36. Drenth, J.P.H. and van der Meer, J.W.M. (2001) Hereditary periodic fever. N. Engl. J. Med. 345, 1748-1757.
37. van der Hilst, J.C., Bodar, E.J., Barron, K.S., Frenkel, J., Drenth, J.P., van der Meer, J.W., et al. (2008) Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore) 87, 301-310.
38. van der Hilst, J.C., Simon, A., and Drenth, J.P. (2003) Molecular mechanisms of amyloidosis. N. Engl. J. Med. 349, 1872-1873.
39. van der Hilst, J.C., Drenth, J.P., Bodar, E.J., Bijzet, J., van der Meer, J.W., and Simon, A. (2005) Serum amyloid A serum concentrations and genotype do not explain low incidence of amyloidosis in hyper-IgD syndrome. Amyloid 12, 115-119. (Pubitemid 40978720)
40. Kluve-Beckerman, B., Liepnieks, J.J., Wang, L., and Benson, M.D. (1999) A cell culture system for the study of amyloid pathogenesis. Amyloid formation by peritoneal macrophages cultured with recombinant serum amyloid A. Am. J. Pathol. 155, 123-133.
41. van der Hilst, J.C., Kluve-Beckerman, B., Bodar, E.J., van der Meer, J.W., Drenth, J.P., and Simon, A. (2008) Lovastatin inhibits formation of AA amyloid. J. Leukoc. Biol. 83, 1295-1299.
42. Pappolla, M.A., Bryant-Thomas, T.K., Herbert, D., Pacheco, J., Fabra, G.M., Manjon, M., et al. (2003) Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 61, 199-205. (Pubitemid 36875301)
43. Scott, H.D. and Laake, K. (2001) Statins for the prevention of Alzheimer's disease. Cochrane Database Syst. Rev. (4), CD003160.
44. Miller, L.J. and Chacko, R. (2004) The role of cholesterol and statins in Alzheimer's disease. Ann. Pharmacother. 38, 91-98.
45. Hoglund, K., Thelen, K.M., Syversen, S., Sjogren, M., von Bergmann, K., Wallin, A., et al. (2005) The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 19, 256-265.
46. Gellermann, G.P., Ullrich, K., Tannert, A., Unger, C., Habicht, G., Sauter, S.R., et al. (2006) Alzheimer-like plaque formation by human macrophages is reduced by fibrillation inhibitors and lovastatin. J. Mol. Biol. 360, 251-257.
47. Hager, E.J., Tse, H.M., Piganelli, J.D., Gupta, M., Baetscher, M., Tse, T.E., et al. (2007) Deletion of a single mevalonate kinase (Mvk) allele yields a murine model of hyper-IgD syndrome. J. Inherit. Metab. Dis. 30, 888-895.
48. Axelrad, M.A., Kisilevsky, R., Willmer, J., Chen, S.J., and Skinner, M. (1982) Further characterization of amyloid-enhancing factor. Lab. Invest. 47, 139-146.
49. Johan, K., Westermark, G., Engstrom, U., Gustavsson, A., Hultman, P., and Westermark, P. (1998) Acceleration of amyloid protein A amyloidosis by amyloid-like synthetic fibrils. Proc. Natl. Acad. Sci. U. S. A. 95, 2558-2563.
50. Sponarova, J., Nystrom, S.N., and Westermark, G.T. (2008) AA-amyloidosis can be transferred by peripheral blood monocytes. PLoS One 3, e3308.
51. van der Hilst, J.C., van der Meer, J.W., Drenth, J.P., and Simon, A. (2007) AL amyloidosis enhances development of amyloid A amyloidosis. Br. J. Dermatol. 156, 748-749.
52. Magy, N., Liepnieks, J.J., Benson, M.D., and Kluve-Beckerman, B. (2003) Amyloid-enhancing factor mediates amyloid formation on fibroblasts via a nidus/template mechanism. Arthritis Rheum. 48, 1430-1437. (Pubitemid 36554543)
53. Yamada, T., Liepnieks, J.J., Kluve-Beckerman, B., and Benson, M.D. (1995) Cathepsin B generates the most common form of amyloid A (76 residues) as a degradation product from serum amyloid A. Scand. J. Immunol. 41, 94-97.
54. van der Hilst, J.C., Kluve-Beckerman, B., van der Meer, J.W., and Simon, A. (2009) Cathepsin D activity protects against development of type AA amyloid fibrils. Eur. J. Clin. Invest. 39, 412-416.
55. Rocken, C., Fandrich, M., Stix, B., Tannert, A., Hortschansky, P., Reinheckel, T., et al. (2006) Cathepsin protease activity modulates amyloid load in extracerebral amyloidosis. J. Pathol. 210, 478-487. (Pubitemid 44830608)
56. Westermark, G.T., Engstrom, U., and Westermark, P. (1992) The N-terminal segment of protein AA determines its fibrillogenic property. Biochem. Biophys. Res. Commun. 182, 27-33.
57. Liu, Y., Cui, D., Hoshii, Y., Kawano, H., Une, Y., Gondo, T., et al. (2007) Induction of murine AA amyloidosis by various homogeneous amyloid fibrils and amyloid-like synthetic peptides. Scand. J. Immunol. 66, 495-500.
58. Csermely, P., Schnaider, T., Soti, C., Prohaszka, Z., and Nardai, G. (1998) The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol. Ther. 79, 129-168.
59. Haslbeck, M., Franzmann, T., Weinfurtner, D., and Buchner, J. (2005) Some like it hot: the structure and function of small heat-shock proteins. Nat. Struct. Mol. Biol. 12, 842-846.
60. Horwitz, J. (1992) Alpha-crystallin can function as a molecular chaperone. Proc. Natl. Acad. Sci. U. S. A. 89, 10449-10453.
61. Jakob, U., Gaestel, M., Engel, K., and Buchner, J. (1993) Small heat shock proteins are molecular chaperones. J. Biol. Chem. 268, 1517-1520.
62. Merck, K.B., Groenen, P.J., Voorter, C.E., de Haard-Hoekman, W.A., Horwitz, J., Bloemendal, H., et al. (1993) Structural and functional similarities of bovine alpha-crystallin and mouse small heat-shock protein. A family of chaperones. J. Biol. Chem. 268, 1046-1052.
63. Mayer, R.J., Landon, M., Laszlo, L., Lennox, G., and Lowe, J. (1992) Protein processing in lysosomes: the new therapeutic target in neurodegenerative disease. Lancet 340, 156-159.
64. Langer, T., Lu, C., Echols, H., Flanagan, J., Hayer, M.K., and Hartl, F.U. (1992) Successive action of DnaK, DnaJ and GroEL along the pathway of chaperone-mediated protein folding. Nature 356, 683-689.
65. Cyr, D.M. (2008) Swapping nucleotides, tuning Hsp70. Cell 133, 945-947.
66. Mayer, M.P. and Bukau, B. (2005) Hsp70 chaperones: cellular functions and molecular mechanism. Cell. Mol. Life Sci. 62, 670-684.
67. Meacham, G.C., Lu, Z., King, S., Sorscher, E., Tousson, A., and Cyr, D.M. (1999) The Hdj-2/Hsc70 chaperone pair facilitates early steps in CFTR biogenesis. EMBO J. 18, 1492-1505. (Pubitemid 29127063)
68. Caplan, A.J., Tsai, J., Casey, P.J., and Douglas, M.G. (1992) Farnesylation of YDJ1p is required for function at elevated growth temperatures in Saccharomyces cerevisiae. J. Biol. Chem. 267, 18890-18895.
69. Sondheimer, N. and Lindquist, S. (2000) Rnq1: an epigenetic modifier of protein function in yeast. Mol. Cell 5, 163-172. (Pubitemid 30105445)
70. Vitrenko, Y.A., Pavon, M.E., Stone, S.I., and Liebman, S.W. (2007) Propagation of the [PIN+] prion by fragments of Rnq1 fused to GFP. Curr. Genet. 51, 309-319.
71. Summers, D.W., Douglas, P.M., Ren, H.Y., and Cyr, D.M. (2009) The type I Hsp40 Ydj1 utilizes a farnesyl moiety and zinc finger-like region to suppress prion toxicity. J. Biol. Chem. 284, 3628-3639.
72. Kudva, Y.C., Hiddinga, H.J., Butler, P.C., Mueske, C.S., and Eberhardt, N.L. (1997) Small heat shock proteins inhibit in vitro A beta(1-42) amyloidogenesis. FEBS Lett. 416, 117-121.
73. Magrane, J., Smith, R.C., Walsh, K., and Querfurth, H.W. (2004) Heat shock protein 70 participates in the neuroprotective response to intracellularly expressed beta-amyloid in neurons. J. Neurosci. 24, 1700-1706. (Pubitemid 38240967)
74. Raman, B., Ban, T., Sakai, M., Pasta, S.Y., Ramakrishna, T., Naiki, H., et al. (2005) AlphaB-crystallin, a small heatshock protein, prevents the amyloid fibril growth of an amyloid beta-peptide and beta2-microglobulin. Biochem. J. 392, 573-581. (Pubitemid 43022737)
75. Wilhelmus, M.M., Boelens, W.C., Otte-Holler, I., Kamps, B., Kusters, B., Maat-Schieman, M.L., et al. (2006) Small heat shock protein HspB8: its distribution in Alzheimer's disease brains and its inhibition of amyloid-beta protein aggregation and cerebrovascular amyloid-beta toxicity. Acta Neuropathol. (Berl.) 111, 139-149.
76. Lee, S., Carson, K., Rice-Ficht, A., and Good, T. (2005) Hsp20, a novel alpha-crystallin, prevents Abeta fibril formation and toxicity. Protein Sci. 14, 593-601. (Pubitemid 40283897)
77. Soo, E.T., Ng, Y.K., Bay, B.H., and Yip, G.W. (2008) Heat shock proteins and neurodegenerative disorders. TheScientificWorldJOURNAL 8, 270-274. (Pubitemid 351549501)
78. Thorn, D.C., Meehan, S., Sunde, M., Rekas, A., Gras, S.L., MacPhee, C.E., et al. (2005) Amyloid fibril formation by bovine milk kappa-casein and its inhibition by the molecular chaperones alphaS- and beta-casein. Biochemistry 44, 17027-17036. (Pubitemid 43007231)
79. Muchowski, P.J., Schaffar, G., Sittler, A., Wanker, E.E., Hayer-Hartl, M.K., and Hartl, F.U. (2000) Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc. Natl. Acad. Sci. U. S. A. 97, 7841-7846.
80. Evans, C.G., Wisen, S., and Gestwicki, J.E. (2006) Heat shock proteins 70 and 90 inhibit early stages of amyloid beta-(1-42) aggregation in vitro. J. Biol. Chem. 281, 33182-33191.
81. Dedmon, M.M., Christodoulou, J., Wilson, M.R., and Dobson, C.M. (2005) Heat shock protein 70 inhibits alpha-synuclein fibril formation via preferential binding to prefibrillar species. J. Biol. Chem. 280, 14733-14740.
82. Tukaj, S., Kotlarz, A., Jozwik, A., Smolenska, Z., Bryl, E., Witkowski, J.M., et al. (2010) Hsp40 proteins modulate humoral and cellular immune response in rheumatoid arthritis patients. Cell Stress Chaperones 15(5), 555-566.